AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06072794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VL-PX10
Description: VL-PX10 is a decellularized product consisting of proteins, lipids, and nucleic acids derived from human placenta mesenchymal stem cells.
Study NCT04977453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-101
Description: Recommended phase 2 dose of GI-101 will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Study NCT04977453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA®)
Description: Pembrolizumab will be administered at a dose of 200 mg as IV infusion Q3W.
Study NCT04977453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered at an approved dose orally.
Study NCT04977453 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Local Radiotherapy
Description: Patients will receive SBRT prior to the first dose of GI-101
Study NCT04977453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI-101A
Description: Recommended phase 2 dose of GI-101A will be administered via IV infusion Q3W up to 2 years (approximately 35 years).
Study NCT05945121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardio-oncology program
Description: Consented patients will undergo an initial CV evaluation as part of standard of care then participate in an 8-week at-home, personalized exercise intervention followed by an additional CV assessment prior to HSCT (after 8-weeks)
Study NCT06444308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CommCare with Mobile Clinical Decision Support (CDS) Application
Description: For those assigned to the CHW arm, management will be assisted by CDS from the CommCare application.
Study NCT06444308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Supervision by Physicians
Description: teleconsultation with a supervising physician
Study NCT06444308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CommCare Application without CDS
Description: The physician will have received training and orientation on the same clinical protocols followed by the CHWs, as well as access to reference materials for these protocols, but the version of the CommCare application used will not provide CDS, but will serve to record and review patient data only.
Study NCT05914623 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: After enrollment, the patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
Study NCT05914623 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: After enrollment, the patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
Study NCT05089019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selpercatinib
Description: Administered orally
Study NCT05089019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Administered orally
Study NCT04837443 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rubber hand illusion
Description: Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.
Study NCT04837443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rubber hand illusion
Description: Tactile sensory threshold from quantitative sensory tests, two point discrimination from cortical senses, pressure pain threshold measured by algometer will be examined during and after the rubber hand burning, which causes changes in body perception.
Study NCT04638088 — intervention group
Intervention type: OTHER
Intervention: assessment of urinary function and erectil function before and after prostatectomy
Description: assessment of urinary function and erectil function before and after prostatectomy performed by robot assisted or conventional laparoscopy or laparotomy will complete
Study NCT05975827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sterile Wound Care Liquid Dressing
Description: Sterile wound care liquid dressing is used in the wound treatment
Study NCT05518500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (Year 1)
Description: Participants will receive Fluzone® Quadrivalent High-Dose in the 2022-2023 flu season.
Study NCT05518500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (Year 2)
Description: Participants will receive FLUAD® Quadrivalent in the 2023-2024 flu season.
Study NCT05518500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flu Vaccine (Year 3)
Description: Participants will receive Flublok Quadrivalent in the 2024-2025 flu season.
Study NCT06318143 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TASSH
Description: Strategy for Hemoglobinopathies (TASSH) containing the essential components of i) Training healthcare workers/providers to be more patient-centered in clinical consultations, ii) Clinical reminders, and iii) Practice facilitation (TCP) known as (TASSH TCP) for SCD management (Figure 1A describes the components of the intervention).
Study NCT04907058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: novel device with a comfortable mask
Description: Using a device with a comfortable mask to supply constant low dose CO2 to treat patients.
Study NCT05804591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Single dose of pregabalin 150mg in a capsule per os 1 hour before start of the operation.
Study NCT05804591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule containing placebo per os 1 hour before start of the operation.
Study NCT04777799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: URGOnight
Description: URGOnight is a daytime brain training solution (CE marked) aim at improve the quality of sleep. The device consists of an electroencephalographic (EEG) measuring strip connected to a mobile application. The latter is available free of charge on Android and iOS in various mobile application stores (Google Play Store and App Store).~URGOnight is a wireless device, it connects via Bluetooth® Low Energy (BLE) to the URGOnight mobile application running on a smartphone. The EEG data is broadcast via a BLE protocol, and the standard Bluetooth® operating distance has a range of 10 meters.~To use the URGOnight solution, the user must authorize the application to access his phone's memory to store his usage data and must also authorize the geolocation of his phone to enable BLE connection. This data is not recorded but is necessary for the proper functioning of the solution.
Study NCT06453746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based cognitive training exercises
Description: The subjects received (i) education on lifestyle modification, (ii) home-based cognitive training exercises with physiotherapist/ physiatrist contact when needed and (iii) a physical training exercises conducted at hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks.
Study NCT06453746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised cognitive training exercises
Description: The subjects received (i) education on lifestyle modification, (ii) supervised cognitive training exercises at hospital (1 weekly session for 12 weeks) and (iii) a physical training exercises conducted in a hospital under the supervision of physiotherapist/ physiatrist (3 weekly session for 12 weeks).~This arm has a duration of 12 weeks.
Study NCT06143566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill
Description: A combination of finerenone 10 mg, empagliflozin 12.5 mg, and losartan 50 mg or 100 mg within a polycapsule.
Study NCT03994081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: XCSITE100
Study NCT03994081 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS
Description: XCSITE100
Study NCT06521749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USB as a stylet
Description: USB used as a bougie
Study NCT06521749 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USB as a bougie
Description: USB used as a bougie
Study NCT06498206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR training
Description: Dichoptic augmented reality training with dual-pathway (parvocellular pathway and magnocellular pathway) and interocular push-pull paradigms developed based on neural deficits in unilateral amblyopia.
Study NCT06498206 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Conventional patching therapy.
Study NCT05026333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Stress Testing
Description: Cognitive and stress study with no product intervention and noninvasive. The high stress/anxiety group will be compared to the low stress/anxiety group in terms of changes from baseline to after the cognitive and stress tests (i.e., 4 laboratory tasks) and metabolite measures.
Study NCT05325736 — intervention group
Intervention type: PROCEDURE
Intervention: sleeve gastrectomy surgery
Description: participants undergoing sleeve gastrectomy surgery
Study NCT05325736 — intervention group
Intervention type: PROCEDURE
Intervention: gastric bypass surgery
Description: participants undergoing gastric bypass surgery
Study NCT05325736 — intervention group
Intervention type: PROCEDURE
Intervention: control
Description: cholecystectomy
Study NCT06226129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadopiclenol
Description: Gadopiclenol for contrast enhanced MRI
Study NCT06474455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839 ；SHR-A2009
Description: SHR-9839 combined with SHR-A2009
Study NCT06474455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839 ； SHR-A1921
Description: SHR-9839 combined with SHR-A1921
Study NCT06474455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839 ； pemetrexed ；carboplatin
Description: SHR-9839 combined with pemetrexed + carboplatin
Study NCT06474455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-9839 ； Almonertinib
Description: SHR-9839 combined with Almonertinib
Study NCT06281132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-341, D956
Description: A single dose of 1 tablet under fasting condition
Study NCT04834661 — intervention group
Intervention type: OTHER
Intervention: surgery inside the primary institution
Description: to perform laparoscopic surgery for colorectal and gastric cancer inside the primary registered medical institution
Study NCT04834661 — intervention group
Intervention type: OTHER
Intervention: surgery outside the primary institution
Description: to perform laparoscopic surgery for colorectal and gastric cancer outside the primary registered medical institution
Study NCT05032040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vudalimab
Description: Monoclonal bispecific antibody
Study NCT05495815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 months of SAT
Description: 6 months of oral suppressive antibiotic therapy
Study NCT05495815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12 months of SAT
Description: 12 months of oral suppressive antibiotic therapy
Study NCT05495815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indefinite SAT
Description: Indefinite oral suppressive antibiotic therapy
Study NCT04798183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3-dimensional scan
Description: Facial 3-dimensional scan according to posture
Study NCT05471076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 30 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).
Study NCT05471076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 100 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).
Study NCT05471076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 426c.Mod.Core-C4b 300 mcg
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).
Study NCT05471076 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via injection as a split dose into the deltoid muscle (both left and right).
Study NCT05471076 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BG505
Description: A soluble, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated at 2 mg/mL, 0.55 mL per vial, in 20 mM Tris, 100 mM NaCl, pH 7.5 will be admixed with 3M-052-AF (5 mcg) + Alum (500 mcg
Study NCT04756427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Citrate 4% Inj Syringe 3Ml
Description: 3 ml of sodium citrate 4% locking solution instilled into the central catheter daily during the period that parenteral nutrition is not infusing, and will be withdrawn and disposed of prior to resuming infusion of parenteral nutrition
Study NCT06106360 — intervention group
Intervention type: DEVICE
Intervention: Locus Health iPhone App
Description: In this pilot study patients are enrolled into three (3) different groups which will vary by the frequency of the queries being sent to the patients during their chemotherapy cycle. The patients will be separated into three groups of 33-34 patients each. Each group will have a different frequency of symptom questions sent to them via the Locus Health iPhone App to determine patient fatigue and the compliance impact of different query cadences. Patients will be assigned to these 3 groups sequentially since the platform could not assign patients to these three cohorts in a random manner.
Study NCT05552846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: Four courses of carboplatin/etoposide/anti-PD-1/PD-L1 every 3 weeks All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after 6 cycle of platinum-based chemotherapy in combination with an anti-PD-1/L1. Then, thoracic radiotherapy of 45 Gy/15 fractions. PD-1/PD-L1 maintenance therapy concurrently and after thoracic radiotherapy at least more than 6 months, or until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
Study NCT05552287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: IFX will be given intravenously at 10 mg/kg at week 0, and 5 mg/kg at weeks 2, 4, and 8 to all patients (induction). Maintenance will start at week 12, and then ideally continue every 6 weeks till week 24 (end of study). IFX trough levels will be measured at weeks 4, 12, and 24. During the maintenance, the IFX dose and/or interval adjustments, the IFX discontinuation or the start of a co-medication (i.e., an immunomodulator) will be possible on indication (i.e., primary nonresponse, secondary loss of response, intolerance to study medication) at the physicians' discretion.
Study NCT04640025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itacitinib
Description: Participants will self-administer itacitinib orally using intact tablets with water and without regard to food.
Study NCT06032871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high frequency chest wall oscillation
Description: Patients receive airway clearance by high frequency chest wall oscillation for 30 minutes twice a day.
Study NCT06032871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Description: Participants received chest physiotherapy twice a day
Study NCT06517446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optokinetic Virtual Reality Stimulation
Description: Optokinetic stimulation;~• A warning will be given by colored balloons rotating clockwise and counterclockwise, starting at 10°/second and gradually increasing up to 60°/second. • Optokinetic stimulation will start with 30 seconds and increase to 150 seconds as the sessions progress. • Patients are asked to focus on a balloon in the moving image. • Stimulations will be given when the patient is sitting, in a semi-tandem stance, in a tandem stance, or standing upright.
Study NCT06517446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation program based on Cawthorne Cooksey exercises
Description: The program will consist of Tracking, VOR, Neck, Static-Dynamic Balance Exercises and Walking training. These exercises depend on the patient's condition; It will be done in sitting, Romberg, semitandem, tandem and walking positions with eyes open and closed. Hard and soft grounds will be used.
Study NCT05164029 — intervention group
Intervention type: OTHER
Intervention: Completion questionnaires/providing biological samples
Description: Participant completes baseline interview at enrollment, then completes questionnaires and provides biological samples at each scheduled study visit.
Study NCT06154109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaopi granules
Description: Xiaopi granules (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
Study NCT06154109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiaopi decoction
Description: Xiaopi decoction (18 g/ bag), 18 g/ time, 2 times/day, 8 days/course.
Study NCT06154109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo does not contain any active pharmaceutical ingredients .
Study NCT05293951 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirror Strengthening Device
Description: Participants will perform resisted task-specific upper limb exercises. During the exercises, participants will pull a resistance cord with their non-affected arm, Participants will complete the exercises while looking at its reflection in a mirror covering their affected arm.~The initial resistance will be chosen based on the participants initial outcome measure results.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions.
Study NCT05293951 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror Therapy
Description: Participants will perform non-resisted task-specific upper limb exercises. During the exercises, participants will be watching their non affected arm reflected in a mirror covering their affected arm.~Repetitions of these exercises will be prescribed according to patient function and strength, and will be increased each week as their ability improves. Sessions will start with 20-minute durations, and should increase in length as the therapy progresses due to the increased repetitions, but are not expected to exceed 30 minutes.~Training duration \& frequency: 20-30 minutes, 5/week for 4 weeks = total 20 sessions.
Study NCT05062187 — intervention group
Intervention type: OTHER
Intervention: Proprioseption in hemiparetics
Description: Proprioception on balance and gait functions in hemiparetic individuals
Study NCT04801810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric hypoxia
Description: Low oxygen exposure to mimic \~8500 feet elevation (experimental).
Study NCT04801810 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normobaric normoxia
Description: Normal oxygen exposure to mimic sea level conditions (sham comparator).
Study NCT05168839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).
Description: In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist.~The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera.~A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits.~An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded.
Study NCT05404828 — intervention group
Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography: WASO, FUSP, TST, TIB, SEF, Global Wake Index, Sleep Latency, AHI
Study NCT05404828 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: STOP-BANG, ISI, ESS, PSQI, MTCQ, ICIQ-F/MLUTS, IRLS, TANGO, SF36
Study NCT05404828 — intervention group
Intervention type: OTHER
Intervention: Blood and urine sample
Description: Na, K, Creat, Osm, Urea
Study NCT05101902 — intervention group
Intervention type: OTHER
Intervention: Pre-Screening
Description: No intervention given
Study NCT05120180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: axillary lymph node dissection with vein branches reservation
Description: Spare the vein branches when ALND being performed
Study NCT05120180 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymph node dissection without vein branches reservation
Description: Don't spare the vein branches when ALND being performed
Study NCT05910073 — intervention group
Intervention type: DEVICE
Intervention: Lamina curved plate
Description: Use of a Lamina Curved plate (Osteobiol® Laboratory) in the treatment of OAC